Guardant Health stock opened at $94.45 on Thursday. Guardant Health has a 52-week low of $27.04 and a 52-week high of $98.25. The firm has a market cap of $6.35 billion and a PE ratio of -33.73.
Guardant Health (NASDAQ:GH) released its earnings results on Tuesday. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.05, Fidelity Earnings reports. The company had revenue of $32.87 million for the quarter, compared to analysts’ expectations of $24.57 million. Guardant Health updated its FY 2019 guidance to EPS.
Several analysts have recently commented on the stock. William Blair reaffirmed an “outperform” rating on shares of Guardant Health in a report on Wednesday. JPMorgan Chase & Co. upped their price objective on shares of Guardant Health from $42.00 to $85.00 and gave the company an “overweight” rating in a report on Wednesday. Finally, Bank of America reaffirmed a “neutral” rating and issued a $60.00 price objective (up from $42.00) on shares of Guardant Health in a report on Thursday, February 28th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Guardant Health presently has a consensus rating of “Buy” and an average target price of $72.50.
Guardant Health Company Profile
Guardant Health, Inc, a precision oncology company, provides non-invasive cancer diagnostics. It offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes from circulating tumor DNA (ctDNA); and GuardantOMNI, a broader panel measuring various genes from ctDNA.
Further Reading: Why are percentage decliners important?